Kexing Biopharm Co., Ltd. (SHA:688136)

Kexing Biopharm Statistics

Total Valuation

Kexing Biopharm has a market cap or net worth of CNY 5.97 billion. The enterprise value is 6.76 billion.

Market Cap	5.97B
Enterprise Value	6.76B

Important Dates

The next confirmed earnings date is Saturday, March 28, 2026.

Earnings Date	Mar 28, 2026
Ex-Dividend Date	n/a

Share Statistics

Kexing Biopharm has 198.11 million shares outstanding. The number of shares has increased by 0.04% in one year.

Current Share Class	198.11M
Shares Outstanding	198.11M
Shares Change (YoY)	+0.04%
Shares Change (QoQ)	-6.28%
Owned by Insiders (%)	50.49%
Owned by Institutions (%)	12.53%
Float	98.08M

Valuation Ratios

The trailing PE ratio is 37.23 and the forward PE ratio is 27.67.

PE Ratio	37.23
Forward PE	27.67
PS Ratio	3.88
PB Ratio	3.48
P/TBV Ratio	4.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	42.41
EV / Sales	4.39
EV / EBITDA	26.22
EV / EBIT	39.35
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.81
Debt / EBITDA	5.42
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 9.50% and return on invested capital (ROIC) is 6.47%.

Return on Equity (ROE)	9.50%
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	6.47%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	6.69%
Revenue Per Employee	1.63M
Profits Per Employee	168,365
Employee Count	971
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Kexing Biopharm has paid 9.98 million in taxes.

Income Tax	9.98M
Effective Tax Rate	5.89%

Stock Price Statistics

The stock price has increased by +47.34% in the last 52 weeks. The beta is 0.73, so Kexing Biopharm's price volatility has been lower than the market average.

Beta (5Y)	0.73
52-Week Price Change	+47.34%
50-Day Moving Average	32.30
200-Day Moving Average	39.54
Relative Strength Index (RSI)	44.32
Average Volume (20 Days)	2,708,336

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kexing Biopharm had revenue of CNY 1.54 billion and earned 159.44 million in profits. Earnings per share was 0.81.

Revenue	1.54B
Gross Profit	1.54B
Operating Income	171.83M
Pretax Income	169.42M
Net Income	159.44M
EBITDA	257.91M
EBIT	171.83M
Earnings Per Share (EPS)	0.81

Balance Sheet

The company has 612.79 million in cash and 1.40 billion in debt, with a net cash position of -785.28 million or -3.96 per share.

Cash & Cash Equivalents	612.79M
Total Debt	1.40B
Net Cash	-785.28M
Net Cash Per Share	-3.96
Equity (Book Value)	1.72B
Book Value Per Share	8.65
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 100.00%, with operating and profit margins of 11.15% and 10.35%.

Gross Margin	100.00%
Operating Margin	11.15%
Pretax Margin	10.99%
Profit Margin	10.35%
EBITDA Margin	16.74%
EBIT Margin	11.15%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 0.28%.

Dividend Per Share	0.08
Dividend Yield	0.28%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.04%
Shareholder Yield	0.24%
Earnings Yield	2.67%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2